Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myeloproliferative Disorders 1Leukemia, Neutrophilic, Chronic 1

Interventions

pembrolizumab 110Specimen Handling 79Magnetic Resonance Spectroscopy 70Carboplatin 67Cisplatin 66Biopsy 57Nivolumab 56Radiotherapy 50Cyclophosphamide 50Paclitaxel 48durvalumab 38Radiation 37Gemcitabine 37olaparib 32Rituximab 32Etoposide 32Dexamethasone 32Doxorubicin 30Docetaxel 30atezolizumab 28Lenalidomide 27Ipilimumab 27Taxes 26Pemetrexed 25Bevacizumab 25Vincristine 24Cytarabine 24Prednisone 23Platinum 23Radiotherapy, Intensity-Modulated 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × fedratinib × 90 days × Clear all
NCT05177211 2026-04-17

Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Active not recruiting
25 enrolled 13 charts
MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Leukemia, Neutrophilic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡